Thymosin Alpha-1 Complete Research Guide: Dosage, Pricing, and Where to Buy

Thymosin Alpha-1: Complete Research Guide 2026

Thymosin Alpha-1 (Tα1) is an immunomodulatory 28-amino acid peptide naturally produced by thymic epithelial cells that has been studied in over 100 clinical trials for applications ranging from hepatitis B and C treatment to cancer immunotherapy adjuvancy and COVID-19 immune restoration. Synthesized as thymalfasin and marketed as Zadaxin® by SciClone Pharmaceuticals, it is approved for medical use in China, Italy, and several other countries, giving it an unusually deep clinical data set compared to most research peptides.

Monthly search volume for “thymosin alpha 1 price” reflects the compound’s high demand in research settings worldwide.

Mechanism of Action in Research

• TLR9 Agonism: Primary mechanism — Tα1 activates Toll-like receptor 9 (TLR9) on plasmacytoid dendritic cells, triggering type I interferon production and innate immune activation
• T-Cell Maturation: Promotes thymic differentiation of CD4+ and CD8+ T-cell precursors, the cellular basis for Tα1’s immunorestorative effects
• NK Cell Enhancement: Increases NK cell cytotoxicity against virally infected and tumor cells
• Cytokine Modulation: Upregulates IL-2, IFN-γ, IFN-α; downregulates IL-4, IL-5 — shifting from Th2 to Th1 immune dominance
• Myeloid Differentiation: Promotes monocyte-to-dendritic cell differentiation, enhancing antigen presentation capacity

Clinical Research Data

Hepatitis B (Most Extensively Studied)

• Meta-analysis of 10 randomized trials: Tα1 + interferon-α achieved HBeAg seroconversion in ~40% of patients vs. ~25% for interferon alone
• Improved HBsAg clearance rates at 12-month follow-up in multiple Phase 3 studies
• Reduced viral load rebound after treatment cessation compared to standard therapy

Cancer Immunotherapy Research

• Randomized trials in NSCLC and hepatocellular carcinoma demonstrate Tα1 as effective adjuvant to standard chemotherapy
• Improved immune recovery markers post-chemotherapy cycles (faster lymphocyte count restoration)
• Phase 2 data: Tα1 + anti-PD-1 checkpoint inhibitor combination shows synergistic tumor response rates in some solid tumors

COVID-19 Research (2020–2021)

• Multiple Chinese hospital studies (retrospective and prospective) documented faster clinical recovery in severe COVID-19 patients treated with Tα1
• Proposed mechanism: restoration of lymphopenia (the hallmark of severe COVID immunosuppression)

Dosage Reference for Research

HPLC Verified

Thymosin Alpha-1

Purity: 99%+ HPLC

Format: Lyophilized Powder

Testing: Third-Party COA

$170

Buy Now

Research Disclaimer: This product is sold strictly for in vitro research and laboratory use only. Not for human consumption. Not medical advice.